Skip to main content
  1. Home
  2. Emerging Tech
  3. News

SpaceX’s rocket relaunch looks set to happen a little later than expected

Add as a preferred source on Google

SpaceX’s rocket program has been grounded since early September when one of its Falcon 9 boosters exploded on a launchpad at Cape Canaveral. Although a little than expected, the company has said it’s now aiming for an “early January” return-to-flight launch.

Last week, December 16 was cited as a likely date for its next launch, but in an announcement on Wednesday the California-based space company said that resuming operations next month “allows for additional time to close-out vehicle preparations and complete extended testing to help ensure the highest possible level of mission assurance prior to launch.” In other words, it wants to be doubly convinced that the disaster can’t happen again.

Recommended Videos

The mission, launching from California’s Vandenberg Air Force Base, will send 10 Iridium Communications satellites into orbit.

An investigation carried out by SpaceX, NASA, and the U.S. Air Force, alongside other industry experts, put the cause of September’s disaster down to a fueling issue that saw liquid oxygen freeze as it was flowing into the Falcon 9’s second stage tank.

The result was a catastrophic explosion that destroyed not only the Falcon 9 rocket but also a $200-million Israeli satellite that Facebook was hoping to use as part of its ambitious plan to bring internet connectivity to remote and underserved communities around the world.

SpaceX CEO Elon Musk called it a “really surprising problem that’s never been encountered before in the history of rocketry,” adding that getting to the bottom of it had proved much more difficult than expected.

Now that it’s uncovered the cause of the disaster and taken action to hopefully prevent anything like it happening again, SpaceX and its clients will be desperate to resume operations and put September’s unfortunate calamity well and truly behind it.

Trevor Mogg
Contributing Editor
Not so many moons ago, Trevor moved from one tea-loving island nation that drives on the left (Britain) to another (Japan)…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more